Integra’s DuraSeal® dural sealant saves healthcare costs according to a study recently published in the Journal of Health ...
August 11 2017 - 8:00AM
Integra LifeSciences (NASDAQ:IART), a leading global medical
technology company, has announced the publication of a new economic
study, “A cost-benefit analysis of using polyethylene glycol
hydrogel sealant versus fibrin glue as a dural sealant for
posterior fossa surgery in the United States.” The study, published
in the Journal of Health Economics and Outcomes Research,
demonstrated an average cost savings of $1,666 per patient when
using Integra’s DuralSeal® dural sealant versus fibrin glue.
Cerebrospinal fluid (CSF) leaks after posterior fossa surgery
are a significant cause of longer hospital stays, hospital
readmissions and other costly post-surgical interventions.
This study demonstrated that the greater clinical effectiveness of
Integra’s DuraSeal dural sealant at preventing CSF leaks compared
to fibrin glue after posterior fossa surgery may help hospitals
reduce costs.
The study, conducted by Dr. Marissa J. Carter, a renowned health
economist, biostatistician, and clinical trial designer, confirmed
a positive, consistent, cost-benefit that averaged $1,666 per
patient for hospitals and surgeons who choose Integra’s DuraSeal
dural sealant instead of fibrin glue. The study included 200
real-world patients in the U.S. who underwent posterior fossa
neurosurgery.
The potential savings are based on the proven clinical efficacy
of DuraSeal versus fibrin glue to reduce incisional cerebrospinal
fluid leaks as found by Than et. al. in their independent clinical
study, “Polyethylene glycol hydrogel dural sealant may reduce
incisional cerebrospinal fluid leak after posterior fossa surgery,”
conducted at the Johns Hopkins University School of Medicine.1
“Integra understands that today’s healthcare providers must
deliver the best treatment options to patients in a cost-effective
way,” said Ajit Patwardhan, MD, senior medical director, Integra
LifeSciences. “Integra’s DuraSeal brand dural sealant is the only
dural sealant indicated for dural closure with both clinical and
economic evidence. This evidence makes DuraSeal the better clinical
choice for surgeons and patients while also meeting the cost
considerations of hospital administrators and operating room
directors.”
Dr. Carter’s health economics study is published online in the
Journal of Health Economics and Outcomes Research, an international
publication that covers all fields and methodologies related to
health economics and employs a rigorous double blind peer review
process. Click here for the full study or visit the Journal
of Health Economics and Outcomes Research web site at
http://www.jheor.org (registration required).
1Than KD, Baird CJ, Olivi A. Polyethylene glycol hydrogel dural
sealant may reduce incisional cerebrospinal fluid leak after
posterior fossa surgery. Neurosurgery. 2008;63 (suppl
1):ONS182-ONS1. https://www.ncbi.nlm.nih.gov/pubmed/18728598).
Integra’s DuraSeal dural sealant is a polyethylene glycol
hydrogel with U.S. FDA approved formulations for use in both the
brain and spine. Since its introduction in 2003, DuraSeal has been
used in more than a million patients around the world. DuraSeal is
distributed in more than 40 countries.
About Integra
Integra LifeSciences is dedicated to limiting uncertainty for
clinicians, so they can concentrate on providing the best patient
care. Integra offers innovative solutions, including leading
plastic and regenerative technologies, in specialty surgical
solutions, orthopedics and tissue technologies. For more
information, please visit www.integralife.com.
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include, but are not limited to,
statements concerning the products and services provided by
Integra. Such forward looking statements involve risks and
uncertainties that could cause actual results to differ materially
from predicted or expected results. Among other things, the
willingness of surgical professionals to use Integra products may
affect the prospects for their use in surgical procedures. In
addition, the economic, competitive, governmental, technological
and other factors, identified under the heading "Risk Factors"
included in Item IA of Integra's Annual Report on Form 10-K for the
year ended December 31, 2016 and information contained in
subsequent filings with the Securities and Exchange Commission
could affect actual results.
CONTACT: Integra LifeSciences Holdings Corporation
Investors
Michael Beaulieu
609-750-2827
Michael.beaulieu@integralife.com
Media
Laurene Isip
609-750-7984
laurene.isip@integralife.com
Integra LifeSciences (NASDAQ:IART)
Historical Stock Chart
From Mar 2024 to Apr 2024
Integra LifeSciences (NASDAQ:IART)
Historical Stock Chart
From Apr 2023 to Apr 2024